Biogen Media |

All Press Releases

Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
1/6/09 12:47 pm EST
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
1/5/09 1:49 pm EST
Phase III Study Showed Rituxan® Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA)
12/19/08 1:30 am EST
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
12/6/08 5:00 pm EST
Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
11/14/08 2:37 pm EST
Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
11/7/08 2:24 pm EST
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
10/30/08 4:00 pm EDT
Biogen Idec to Present at the Oppenheimer 19th Annual Healthcare Conference
10/28/08 10:57 am EDT
Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
10/27/08 9:00 am EDT
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
10/23/08 6:30 pm EDT

Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
12/6/08 5:00 pm EST
Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
11/14/08 2:37 pm EST
Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
11/7/08 2:24 pm EST
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
10/30/08 4:00 pm EDT
Biogen Idec to Present at the Oppenheimer 19th Annual Healthcare Conference
10/28/08 10:57 am EDT
Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
10/27/08 9:00 am EDT
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
10/23/08 6:30 pm EDT
Biogen Idec Reports Third Quarter 2008 Results
10/21/08 7:15 am EDT
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
10/9/08 4:00 pm EDT
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
10/7/08 1:30 am EDT